| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares are trading lower on Friday. The company released its third-quarter financial results.
What To Know: Ginkgo Bioworks reported a loss of $1.45 per share versus estimates for a loss of $1.24 per share and a loss of $1.08 per share in the same period last year, representing a 34.26% increase in losses year over year.
The company reported quarterly sales of $38.8 million, versus the analyst consensus estimate of $38.9 million, marking a 56.39% decrease compared to sales of $89.0 million in the same period last year.
Total revenue was $39 million in the third-quarter, down 56% from $89 million last year, which included $45 million in non-cash revenue from a terminated customer deal. Without accounting for the deal, revenue fell 11% year over year.
Cell Engineering revenue was $29 million in the third-quarter, down 61% from $75 million last year, which included $45 million in non-cash revenue. Excluding that, revenue was only slightly lower than the prior year.
Third-quarter adjusted EBITDA was negative $56 million, down from negative $20 million in the comparable prior year period, mainly due to the non-cash deferred revenue release in the prior year.
The company ended the quarter with cash, cash equivalents and marketable securities of $462 million as of Sept. 30, 2025.
Ginkgo Bioworks affirmed its fiscal year 2025 revenue outlook in the range of $167 million to $187 million, versus the analyst consensus estimate of $177.1 million.
DNA Price Action: Ginkgo Bioworks Holdings shares were down 21.95% at $8.82 at the time of publication on Friday, according to Benzinga Pro.
Read Next:
Image: Shutterstock
Posted In: DNA
